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Abstract
Background: Circulating tumor cells (CTCs) have been associated with prognosis especially in breast cancer and
have been proposed as a liquid biopsy for repeated follow up examinations. Molecular characterization of CTCs is
difficult to address since they are very rare and the amount of available sample is very limited.
Methods: We quantified by RT-qPCR CK-19, MAGE-A3, HER-2, TWIST1, hTERT a+b+, and mammaglobin gene
transcripts in immunomagnetically positively selected CTCs from 92 breast cancer patients, and 28 healthy
individuals. We also compared our results with the CellSearch system in 33 of these patients with early breast
cancer.
Results: RT-qPCR is highly sensitive and specific and can detect the expression of each individual gene at the one
cell level. None of the genes tested was detected in the group of healthy donors. In 66 operable breast cancer
patients, CK-19 was detected in 42.4%, HER-2 in 13.6%, MAGE-A3 in 21.2%, hMAM in 13.6%, TWIST-1 in 42.4%, and
hTERT a+b+ in 10.2%. In 26 patients with verified metastasis, CK-19 was detected in 53.8%, HER-2 in 19.2%, MAGE-
A3 in 15.4%, hMAM in 30.8%, TWIST-1 in 38.5% and hTERT a
+b
+in 19.2%. Our preliminary data on the comparison
between RT-qPCR and CellSearch in 33 early breast cancer patients showed that RT-qPCR gives more positive
results in respect to CellSearch.
Conclusions: Molecular characterization of CTCs has revealed a remarkable heterogeneity of gene expression
between breast cancer patients. In a small percentage of patients, CTCs were positive for all six genes tested, while
in some patients only one of these genes was expressed. The clinical significance of these findings in early breast
cancer remains to be elucidated when the clinical outcome for these patients is known.
Background
Metastasis is a multi-stage process [1] that selects for
Circulating Tumor Cells (CTCs) that can infiltrate, sur-
vive in and colonize distant organs [2]. Recent advances
in this field are supportive for the early dissemination
model of metastasis, through the observation that Disse-
minated Tumour Cells (DTCs) isolated from bone mar-
row or lymph nodes display disparate changes on all
levels of genomic resolution as compared to primary
tumor cells [3]. Cancer cell dissemination may be fol-
lowed by a dormancy period before relapse in one or
more organs [4]. Research on DTCs and CTCs present
nowadays a challenge, as these cells are well defined
targets for understanding tumour biology and tumour
cell dissemination in cancer patients [5], and will open
new avenues for the early detection of metastatic spread
and its successful treatment.
CTCs have been of interest to the medical and
research communities for over a century [6]. Data from
European groups have sustained the prognostic impact
of DTCs in the BM of breast cancer patients [7]. How-
ever, sequential peripheral blood analysis is more conve-
nient than BM analyses in patients with solid tumors.
CTCs detection and enumeration in breast cancer has
been established in several clinical studies, showing a
correlation with decreased progression-free survival and
overall survival in operable [8-12] and advanced breast
cancer [13,14]. Our group has previously shown that the
detection of CTCs in peripheral blood of early breast
cancer patients before and after chemotherapy through
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is of prognostic significance [8-12]. We have recently
shown that the detection of CTCs post-chemotherapy in
breast cancer patients is associated with involvement of
more than three axillary lymph nodes with significantly
increased clinical relapses and disease-related deaths
[15]. Enumeration and molecular characterization of
CTCs can be used as a liquid biopsy for repeated follow
up examinations in a variety of human cancers [16-18]
and may play a major role in helping to guide targeted
therapy [16-20].
Recently, the phenotypical and functional variety of
breast cancer cells in primary tumors as well as in
DTCs is shown for recognized prognostic factors, such
as HER-2/neu [19-21], ER, PR [21] and cancer stem cell
markers such as CD44, CD24 or ALDH1 [22,23].
Further molecular characterization of CTCs is important
not only to confirm their malignant origin but also to
identify diagnostically and therapeutically relevant tar-
gets to help stratifying cancer patients for individual
therapies [18].
CTCs are rare, comprising a few cells per 10
6 hemato-
logic cells in blood of patients with metastasis; hence
their isolation presents a tremendous technical challenge
[24-26]. DTCs and CTCs can now be detected and char-
acterized at the single cell level [27]. Recent technical
advancements in the detection and characterization of
CTCs include highly sensitive RT-qPCR [28-30], image-
based immunologic approaches like the FDA approved
CellSearch system [31], or a combination of molecular
and imaging methods [32]. Lately a membrane microfil-
ter device for single stage capture and electrolysis of cir-
culating tumor cells [33] as well as a CTCs microchip
were developed [34]. Multimarker RT-PCR can increase
sensitivity and specificity of CTCs detection [11,23,26].
By using a multi-marker assay in CTCs in early breast
cancer, we have shown that CK-19, Mammaglobin,a n d
HER-2 positive CTCs are associated with shorter disease
free survival [11]. Recently, EpCAM, MUC-1 and HER2
transcripts were detected in CTCs and a major propor-
tion of CTCs in metastatic breast cancer patients
showed EMT and tumor stem cell characteristics [23].
The purpose of this study was to quantify by RT-
qPCR CK-19, MAGE-A3, HER-2, TWIST1, hTERT a+b
+,a n dmammaglobin gene transcripts in immunomag-
netically positively selected CTCs. We analyzed CTCs
from 92 breast cancer patients and 28 healthy indivi-
duals and compared our results with the CellSearch sys-
tem in 33 of these patients with early breast cancer.
Methods
Cell lines
The human mammary carcinoma cell lines SKBR-3,
MDA-MB-231 and MCF-7 were used for the
development of the assay and the generation of gene
specific quantification calibrators. Cells were counted in
a hemocytometer and their viability was assessed by try-
pan blue dye exclusion. Serial dilutions of a known
number of cells corresponding to 1-1000 cells, for which
total RNA isolation and cDNA synthesis was performed,
were prepared. These cDNAs were kept in aliquots at
-20°C and used for the validation of the assay, prior to
the analysis of patient’s samples.
Patients
A total of 92 consecutive patients with breast cancer
were studied, 66 patients with stage I-III operable breast
cancer at least 2 weeks after the removal of the primary
tumor and before the initiation of adjuvant chemother-
apy and 26 patients with verified metastasis. A group of
28 healthy female blood donors were used as control.
For every patient peripheral blood (20 mL in EDTA)
was obtained as previously described [28,29]. All
patients signed an informed consent to participate in
the study which was approved by the Ethics and Scienti-
fic Committees of our Institution.
RNA extraction-mRNA purification
T h ee n t i r eR T - q P C Ra s s a yp r o c e d u r ef o rg e n ee x p r e s -
sion in CTCs is outlined in Figure 1.
After dilution of peripheral blood with 20 mL phos-
phate buffered saline (PBS, pH 7.3), peripheral blood
mononuclear cells (PBMCs) were obtained by gradient
density centrifugation using Ficol-PaqueTM PLUS (GE
Healthcare, Bio-Sciences AB) at 670 g for 30 min at
room temperature. The interface cells were removed,
washed twice with 40 mL of sterile PBS (pH 7.3, 4°C), at
530 g for 10 min, and resuspended in 1 mL of PBS.
Immunomagnetic Ber-EP4 coated capture beads (Dyna-
beads
® Epithelial Enrich, Invitrogen) were used to
enrich for epithelial cells, according to manufacturer’s
instructions. We kept for each sample both isolated
fractions: the CTC and corresponding PBMC fraction.
Total RNA isolation was performed with TRIZOL (Invi-
trogen, USA). All RNA preparation and handling steps
took place in a laminar flow hood, under RNAse-free
conditions. The isolated RNA from each fraction was
dissolved in 20 μL of RNA storage buffer (Ambion,
USA) and stored at -70°C until used. RNA concentra-
tion was determined by absorbance readings at 260 nm
using the Nanodrop-1000 spectophotometer (NanoDrop,
Technologies, USA). mRNA was isolated from the total
RNA, using the Dynabeads mRNA Purification kit (Invi-
trogen, USA) according to the manufacturer’si n s t r u c -
tions. cDNA synthesis was performed using the
SuperScript™ First-Strand Synthesis System (Invitrogen,
USA) in a total volume of 20 μL according to the manu-
facturer’s instructions.
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Multiplex RT-qPCR
Multiplex RT-qPCR was performed for CK-19, HER-2,
MAGE A3 and PBGD. Primers and dual hybridization
probes were de novo in-silico designed (Table 1). Only
for CK-19 we used the primers and probes previously
reported [29], while for HER-2, we used the forward pri-
mer previously reported [20]. In-silico design was per-
formed by using Primer Premier 5.0 software (Premier
Biosoft, CA, USA). All primers and probes were
designed to match the assay conditions, such as ampli-
con sizes, and melting temperatures. The specificity of
all primer and hybridization probe sequences was first
tested by homology searches in the nucleotide database
(NCBI, nucleotide BLAST). Each probe set included a
3’-fluorescein (F) donor probe and a 5’- LC acceptor
probe that was different for each gene set: CK-19 at 640
nm, MAGE A3 at 610 nm, HER-2 at 670 nm, PBGD at
705 nm. A color compensation test was performed by
using pure dye spectra so that spectral overlap between
dyes was corrected [35]. All oligonucleotides were
s y n t h e s i z e da tF O R T H ,H e r a k l i o n ,C r e t e ,a n dd u a l
hybridization probes were obtained from TIB MOL,
Germany. Multiplex RT-qPCR reactions were performed
in the LightCycler 2.0 (Roche, Germany). The amplifica-
tion reaction mixture (total volume of 10 μL) contained
1 μL of the PCR Synthesis Buffer (10Χ), 1.25 μLo f
MgCl2 (50 mM), 0.4 μLd N T P s( 1 0m M ) ,0 . 8μLB S A
(10 μg/μL), 0.4 μL Hot Start DNA polymerase (Plati-
num, 5 U/μL, Invitrogen, USA), 1 μLo fam i x t u r ec o n -
taining all eight primers (10 μΜ for each), 0.5 μLo fa
mixture containing all eight dual hybridization probes (4
μM for each) and DEPC-H2O (added to the final
volume). Cycling conditions: 95°C/3 min; 45 cycles of
95°C/10 s, annealing at 60°C/60 s and extension at 72°
C/30 s.
20 mL 
Peripheral
blood
Ficoll
gradient
PBMCs
mRNA purification
cDNA 
synthesis
RT-qPCR
CK-19 MAGE A3
HER2 PBGD
Positive
selection
(EpCAM)
Apply magnet
hTERT Į+ȕ+
TWIST1
Figure 1 Schematic diagram of the entire analytical procedure.
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Single RT-qPCR was performed for hTERT a
+b
+,
TWIST1 and mammaglobin. For hTERT a
+b
+ we used
the same primers and probe and for mammaglobin the
same primers as previously reported [36,37], while we
designed novel hydrolysis probe and primers for
TWIST1 and a novel hydrolysis probe for Mammaglobin
(Table 1). The amplification reaction mixture (total
volume of 10 μL) contained 1 μL of the PCR Synthesis
Buffer (10Χ), 0.5 μLo fM g C l 2 (50 mM), 0.2 μLd N T P s
(10 mM), 0.15 μLB S A( 1 0μg/μL), 0.1 μLH o tS t a r t
DNA polymerase (Platinum, 5 U/μL, Invitrogen, USA),
0.5 μL of each primer (10 μΜ), 1.0 μL of each hydrolysis
probe (3 μM) and DEPC-H2O (added to the final
volume). Incubation conditions: 95°C/3 min; 45 cycles of
95°C/10 sec, annealing at 63°C/20 sec for TWIST1, 65°
C/20 sec for hTERT a+b+ [36], 55°C/20 sec for Mam-
maglobin and extension at 72°C/20 sec.
To ensure that amplifiable material was present in all
specimens and to avoid false-negative results, real-time
amplification of the reference gene PBGD was per-
formed for all samples. To reduce the risk of contamina-
tion, each procedure such as RNA extraction, cDNA
synthesis, preparation of the RT-qPCR reactions and
thermocycling, were performed in separate rooms while
preparation of the cDNA and PCR reactions were set up
in different PCR-hoods. A positive (cell line cDNA) and
a negative control (H2O) were included in all runs.
Preparation of RT-qPCR quantification calibrators
For the development and analytical evaluation of the assay,
we generated individual PCR amplicons corresponding to
the gene-targets studied that would serve as quantification
calibrators [36]. For this purpose, total RNA was extracted
from SKBR-3, MDA-MB-231 and MCF-7 cells; cDNA was
synthesized and served as a template for the amplification
of each target of interest by the above described RT-qPCR.
PCR products were purified using PureLink™ PCR Purifi-
cation Kit (Nitrogen, USA) and amplicons for each gene
were quantified in the Nanodrop-1000 spectophotometer
(NanoDrop, Technologies, USA). Concentrations were
converted to copies/μLb yu s eo ft h eA v o g a d r oc o n s t a n t
and the molecular weight of each amplicon number of
bases of the PCR product multiplied by the mean molecu-
lar weight of a pair of nucleic acids which is 660 [38]. A
standard stock solution containing all amplicons
Table 1 Oligonucleotide primers and probes
Target gene Primer or probe Sequence (5’-3’) Tm (°C) Amplicon
Size (bp)
Accession
No.
CK-19 Forward CGG GAC AAG ATT CTT GGT 52.4 142 Y00503
Reverse CGT TGA TGT CGG CCT CCA 60.4
Probe TGT CCT GCA GAT CGA CAA CGC CC-FL 71.0
LCRed640-CTG GCT GC AGA TGA CTT CCG AAC C-PH 69.0
MAGE A3 Forward TCG GTG AGG AGG CAA GGT T 60.1 147 NM_005362
Reverse GAT GAC TCT GGT CAG GGC AA 57.8
Probe GGA GGA GCA CTG AAG GAG AAG ATC TGC-FL 69.2
LC610-AGT GGG TCT CCA TTG CCC AGC TC-PH 68.4
HER-2 Forward AGC CGC GAG CAC CCA AGT 63.6 188 M11730
Reverse CCT GCA CCT CCT GGA TAT CCT G 63.3
Probe CAC CTA CCT GCC CAC CAA TGC CA-FL 70.6
LC670-CTG TCC TTC CTG CAG GAT ATC CAG GA-PH 68.8
PBGD Forward CCT GAG GCA CCT GGA AGG AG 62.5 163 NM_000190
Reverse ATC TTC ATG CTG GGC AGG GA 61.8
Probe TGT GCC AGT AGC CGT GCA TAC AGC-FL 69.1
LC705-GAA GGA TGG GCA ACT GTA CCT GAC TG-PH 67.3
hTERT Forward TCA AGG TGG ATG TGA CGG G 59.2 347 AF015950
Reverse GGA CTT GCC CCT GAT GCG 61.7
Probe 6FAM - CGT GTT CTG GGG TTT GAT GAT GCT GGC GA - TMR 74,5
hMAM Forward ACG GAT GAA ACT CTG AGC AAT G 59.4 106 U33147
Reverse CAG TTC TGT GAG CCA AAG GT 54.9
Probe 6FAM-TGA GGT GTT TAT GCA ATT AAT ATA TGA CAG CAG TC -XT- -PH 64.2
TWIST1 Forward GGC CGG AGA CCT AGA TGT 54,2 150 NM_000474
Reverse CAC GCC CTG TTT CTT TGA AT 57,8
Probe 6FAM-TGG ACA GTC TAG AGA CT
C TGG AGC TGG-BBQ
66,6
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10copies/μL for each gene transcript
was prepared. Serial dilutions of this stock amplicon solu-
tion in DNase/RNase-free water ranging from 10
5copies/
μLt o1 0c o p i e s / μL served as quantification calibrators
throughout the study. For quantification of each gene
transcript, an external calibration curve was obtained by
plotting the concentration of each quantification calibrator
expressed as copies/μL vs corresponding quantification
cycle (Cq).
Cell Search
We enumerated CTCs using the CellSearch System (Veri-
dex, USA) in peripheral blood samples of 33 patients with
early breast cancer for which an extra volume of periph-
eral blood was available. 23 mL of blood were collected in
CellSave Preservative Tubes (Veridex, USA). In brief, 16.5
mL of whole blood was centrifuged for 10 min at 800 × g
and plasma was aspirated. 10 mL of dilution buffer was
added and the total blood mixture was layered on 5 mL of
Histopaque -1083 and centrifuged for 10 min at 400 × g.
Buffer was aspirated and the buffy coat was collected and
added in 6.5 mL of total blood. Centrifugation at 800 × g
for 10 min followed and the sample was processed into
the CellTracks Autoprep System where the Cell Search
Circulating Tumor Cell Kit was used (Veridex Warren,
NJ.) according to manufacturer’s instructions. In brief, this
kit contains ferrofluid particles coated with anti-EpCAM
antibodies, phycoerythrin conjugated anti-CK antibodies
recognizing cytokeratins (8, 18 and/or 19) to specifically
identify epithelial cells and allophycocyanin-conjugated
anti-CD45 antibody in order to identify white blood cells.
Nuclear dye (4’,6-diamidino-2-phenylindole/DAPI) was
also added so as to fluorescently label the cell nuclei. In
the final processing step, the selected cells were trans-
ferred automatically to a cartridge in a MagNest cell pre-
sentation device after an incubation of at least 20 min in
the dark at room temperature. The MagNest was then
moved to Cell Tracks Analyzer II, which contains a semi-
automated fluorescent microscope (4 fluorescent filter
cubes) which captures images of fluorescently labeled cells
that are immunomagnetically selected and aligned, cover-
ing the entire surface of the cartridge. The images are pre-
sented in a gallery format to the operator which classifies
according to predetermined criteria (specified by Veridex)
for the presence of CTCs. A cell is classified as epithelial
cell (CTC) if it meets the following: Nearly round to oval
morphology, visible nucleus within the cytoplasm, cytoker-
atin-phycoerythrin positive, DAPI positive, CD45-allophy-
cocyanin negative and size of at least 4 μm.
Results
Validation of CTC gene expression RT-qPCR assay
The ability to multiplex greatly expands the power of
qPCR analysis. Multiplexing requires the presentation of
evidence demonstrating that accurate quantification of
multiple targets in a single tube is not impaired, i.e.,
that assay efficiency and the LOD are the same as when
the assays are run in uniplex fashion. This concern is of
particular importance when targets of appreciably lower
abundance are coamplified with highly abundant targets
[39]. For this reason we performed extensive experi-
ments to validate the performance of multiplex RT-
qPCR.
Specificity
In multiplex RT-qPCR, we checked the specificity of pri-
mers and dual hybridization probes both in the presence
and absence of each gene target. So, in individual glass
capillaries we tested the specificity of all oligonucleotides
when only one individual gene target was present as a
template. Each primer and dual hybridization probe pair
amplifies specifically only the corresponding target
amplicon (Additional file 1 Figure S1). None of the pri-
mers and dual hybridization probes gave any signal for
any of the gene target transcripts when five different
genomic DNAs (500 ng/μL), were analyzed.
Limit of Detection and Linearity
A low detection limit is extremely important for CTC
analysis. For this reason, before proceeding to patients’
samples, we evaluated the limit of detection of the
developed CTC gene expression RT-qPCR assay by
using quantification calibrators containing a known
number of copies/μL, prepared as described [36,39]. For
each gene target a calibration curve was generated using
serial dilutions of these standards in triplicate for each
concentration, ranging from 10
5copies/μLt o1 0c o p i e s /
μL and showed linearity over 10
5copies/μLt o1 0
2copies/
μL with correlation coefficients larger than 0.99 in all
cases, indicating a precise log-linear relationship (Addi-
tional file 2 Figure S2). The detection limit, quantifica-
tion limit, mean slope and intercept of the calibration
curve as well as the PCR efficiency expressed as E = [10
-
1/slope] -1 for each gene target are shown in Supplemen-
tal data, Table 1. In all cases, the LOD (LOD = 3.3 ×
SDst/slope), was found to correspond to 3 copies/μL
while the limit of quantification (LOQ) defined as 3
times the LOD was equal to 10 copies/μL. Before pro-
ceeding to patients’ samples, we evaluated the perfor-
mance of the developed assays in the SKBR-3 cell line
for all gene targets, except TWIST-1,w h e r et h eM D A -
MB-231 cell line and hTERT a+b+ where the MCF-7
cell line were used. We performed a dilution study for
each gene target using cDNA, corresponding to 1000
cells by using serial dilutions in triplicate for each con-
centration, ranging from 1000 to 1 cells. In these sam-
ples, we checked the quantification cycles of each target
gene CK-19, HER-2, MAGE A3 and PBGD.O u rr e s u l t s
showed linearity over the entire quantification range (1-
1000 cells/μL) and correlation coefficients greater than
Strati et al. BMC Cancer 2011, 11:422
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relationship.
Precision
Repeatability or intra-assay variance (within-run preci-
sion) of the multiplex RT-qPCR, was evaluated by
repeatedly analyzing 4 cDNA samples corresponding to
1, 10, 100 and 1000 SKBR-3 cells, in the same assay, in
3 parallel determinations. Intra-assay variance expressed
a st h eS D so ft h eC qv a r i a n c e[ 3 9 ]f o rCK-19,r a n g e d
from 0.15 to 0.48, while for MAGE A3 ranged from 0.22
to 0.58, for HER-2 ranged from 0.10 to 0.39, and for
PBGD ranged from 0.16 to 0.41 (Table 2). Intra-assay
variance expressed as within-run CVs of copies/μLr a n -
ged for CK-19, from 10% to 31%, for MAGE A3 from
13% to 33%, for HER-2 from 6.2% to 29%, and for
PBGD from 1.3% to 25% (Table 2). Reproducibility or
inter-assay variance (between-run precision) [39] of the
multiplex RT-qPCR assay, was evaluated by analyzing
the same cDNA sample, repre s e n t i n g1 0 0S K B R - 3c e l l s
and kept frozen in aliquots at -20°C, over a period of
one month on 5 separate assays performed in 5 different
days. Between-run CVs were 21% for CK-19,1 7 %f o r
MAGE A3, 24% for HER-2 and 19% for PBGD (Table 2).
Comparison between single and multiplex RT-qPCR
We evaluated the performance of multiplex RT-qPCR
by analyzing in parallel the same cDNAs corresponding
to 1-1000 SKBR-3 cells and 26 cDNAs from patients’
samples by both single and multiplex assays for CK-19
and PBGD. A successful RT-qPCR multiplex reaction is
achieved when multiplex and single assays performed
simultaneously on the same run result in similar quanti-
fication cycles (Cq) values for the amplification of a par-
ticular gene. The multiplex assay correlates very well
with single RT-qPCR for all genes studied when the
SKBR3 cell line were used (data not shown), while when
clinical samples were tested, the multiplex assay corre-
lates very well with single RT-qPCR for both CK-19 (R
2
= 0.9931) and PBGD (R
2 = 0.8312).
Gene expression profile of CTCs in breast cancer
We quantified CK-19, MAGE-A3, HER-2, TWIST1,
hTERT a+b+,a n dmammaglobin gene transcripts in
immunomagnetically positively selected CTCs from 92
breast cancer patients, and 28 healthy individuals used
as a control group. For each patient, we analyzed both
the CTC and the corresponding PBMC fraction, used as
a negative control. RNA quality of all samples was
checked by PBGD expression, used as a reference gene.
Only samples that were positive for PBGD expression
were further processed. The expression levels of these
genes, expressed as copies/mL of peripheral blood, dif-
fered significantly between the healthy normal donors
and breast cancer patients, both for the early and the
verified metastasis group (Figure 2). We observed a high
qualitative and quantitative heterogeneity in the gene
expression profile in the CTCs fraction for each indivi-
dual patient in both groups. As can be seen in Figure 3,
in a small percentage of patients (3%), CTCs were posi-
tive for all six genes tested, while in some patients only
one of these genes was expressed.
Healthy individuals
When using Dynabeads we always have a contamination
of white blood cells isolated together with CTCs. To
overcome this we have also analyzed 28 healthy female
volunteers. In this group we did not observe any expres-
sion for CK-19, MAGE A3, HER-2, hTERT a+b+, and
Mammaglobin. For this reason all samples that showed
amplification were regarded as positive for these genes.
In the same group of healthy individuals we found only
one sample with very low expression for TWIST1 (Cq >
37) and have used this Cq as a cut-off for all our sam-
ples. According to these results we concluded that con-
tamination of white cells did not affect our expression
Table 2 Intra-assay and inter-assay precision of the
multiplex RT-qPCR for CK-19, MAGE A3, HER2 and PBGD.
SKBR-3,
Number of
cells
Quantification cycle
(Cq),
Mean Cq (SD)
Copies,
Mean Copies
(SD)
CV%
CK-19 Intra assay precision (n = 3)
1 29.75 (0.15) 218 (± 22) 10
10 25.90 (0.17) 3.12 (± 0.34) × 10
3 11
100 21.87 (0.17) 5.07 (± 0.61) × 10
4 12
1000 18.37 (0.48) 5.8 (± 1.8) × 10
5 31
Inter assay precision (n = 5)
100 21.70 (0.27) 5.8 (± 1.2) × 10
4 21
MAGE A3 Intra assay precision (n = 3)
1 34.51 (0.58) 43 (± 14) 33
10 30.22 (0.31) 6.0 (± 1.1) × 10
2 18
100 26.58 (0.22) 5.79 (± 0.75) × 10
3 13
1000 23.25 (0.42) 4.7 (± 1.1) × 10
4 23
Inter assay precision (n = 5)
100 26.41 (0.21) 5.18 (± 0.87) × 10
2 17
HER-2 Intra assay precision (n = 3)
1 33.38 (0.39) 14 (± 4) 29
10 28.81 (0.10) 321 (± 20) 6.2
100 24.72 (0.11) 5.33 (± 0.38) × 10
3 7.2
1000 21.48 (0.37) 5.0 (± 1.2) × 10
4 24
Inter assay precision (n = 5)
100 24.43 (0.39) 6.6 (± 1.6) × 10
3 24
PBGD Intra assay precision (n = 3)
10 32.43(0.16) 27 (± 3) 11
100 29.31(0.020) 227 (± 3) 1.3
1000 26.26 (0.41) 19 (± 4.8) × 10
2 25
Inter assay precision (n = 5)
100 29.28 (0.27) 324 (± 60) 19
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to the presence of isolated leucocytes, works as an inter-
nal positive control for us since it is giving us the infor-
mation that isolated RNA is of good quality.
Early breast cancer
There was a high heterogeneity in CTC gene expression
in early breast cancer patients (Figure 3). There were 22
patients positive for 1 gene (33.3%), 15 patients positive
1
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Figure 2 Quantification of CK-19, MAGE-A3, HER-2, TWIST-1, hMAM (Mammaglobin), and h-TERT a+b+ transcripts in CTCs (copies/mL of
peripheral blood).
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RT-qPCR.
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Page 7 of 12for 2 genes (22.7%), 7 patients positive for 3 genes
(10.6%), 2 patients positive for 5 genes (3%), 2 patients
positive for all 6 genes studied (3%), while in 18 patients
we didn’t detect CTCs at all (27.2%). We found 28/66
(42.4%) patients positive for CK-19, 14/66 (21.2%) posi-
tive for MAGE-A3, 9/66 (13.6%) positive for HER-2,2 8 /
66 (42.4%) positive for TWIST1, 7/66 (10.2%) positive
for hTERT a+b+ and 9/66 (13.6%) positive for hMAM.
In early breast cancer, the percentage of double positives
for epithelial marker CK-19 and mesenchymal marker
TWIST1 is 14/66 (21.2%). 14 out of 66 patients (21.2%)
showed only epithelial characteristics while other 14
patients showed only mesenchymal characteristics. 24
out of 66 patients (36.4%) were negative for both of
these markers.
Metastatic breast cancer
We observed a high heterogeneity in CTC gene
expression in breast cancer patients with verified
metastasis (Figure 3). We found 14/26 patients posi-
tive for CK-19 (53.8%) 4/26 positive for MAGE-A3
(15.4%), 5/26 patients positive for HER-2 (19.2%), 10/
26 (38.5%) positive for TWIST-1, 5/26 (19.2%) positive
for hTERT a+b+ and 8/26 (30.8%) positive for
hMAM. In this group we found 7 patients positive for
1 gene (26.9%), 4 patients positive for 2 genes (15.4%),
6 patients positive for 3 genes (23.1%), 2 patients posi-
tive for 4 genes (7.7%), 1 patient positive for 5 genes
(3.85%), while in 6 patients we didn’td e t e c tC T C sa t
all (23.1%).
Comparison between CellSearch and RT-qPCR in operable
breast cancer
We analyzed a small number of clinical samples (33
patients with early breast cancer belonging to the group
of 66 patients that we analyzed also by RT-qPCR) by
both multiplex real time RT-qPCR and the CellSearch
System (Veridex, USA). Unfortunately we could only
analyze samples for which an extra volume of peripheral
blood could be available, since we decided to include
this comparison study in the last phase of the recruit-
ment period (Figure 4). The concordance between Cell-
Search and RT-qPCR for these patients was 18/33
(54.5%). Specifically, 11 patients were found positive and
7 patients were found negative for CTCs by both assays,
while 12 patients were found positive by RT-qPCR and
negative by CellSearch and 3 patients were found posi-
tive by CellSearch and negative by RT-qPCR. Using the
CellSearch, 7/33 (21.2%) patients were found to have ≥
2CTCs/23 mL of peripheral blood and 7/33 (21.2%)
patients had one CTC/23 mL of peripheral blood. Using
RT-qPCR, 23/33 patients were found positive for at
least one gene (69.7%): 13/33 (39.4%) patients were posi-
tive for CK-19, 9/33 (27.3%) patients were positive for
MAGE-A3, 5/33 (15.1%) patients were positive for HER-
2, 3/33 (9.1%) patients were positive for hTERT a+b+,
13/33 (39.4%) patientsw e r ep o s i t i v ef o rTWIST-1 and
6/33 (18.2%) patients were positive for mammaglobin.
In the group of 14/33 (42.4%) patients that were found
positive for CTCs by the Cell Search, 11/33 were also
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Page 8 of 12positive for at least one gene by RT-qPCR (78.6%) and 3
patients were negative (21.4%). Among the 19/33
patients that were found negative for CTCs by Cell-
Search, 12 were positive for at least 1 gene (63.2%) and
7/33 patients were negative (36.8%) by RT-qPCR.
Patients who tested positive for CTCs, by either Cell-
Search or gene expression profile, were found to express
TWIST1 transcript compared to patients with a negative
CTC test by both methods (53.8% vs. 0%; P = 0.013,
Fisher’s exact test).
Discussion
Nowadays there is an urgent need for biomarkers for
real-time personalized monitoring of the efficacy of sys-
temic adjuvant therapy. At present, the success or fail-
ure of anti-cancer therapies is only assessed
retrospectively by the absence or presence of overt
metastases during the post-operative follow-up period.
However, overt metastases are, in general, incurable by
most current therapies. Monitoring of CTCs can provide
new insights into the clonal selection of resistant tumor
cells under biological therapies. The CellSearch is the
only US Food and Drug Administration (FDA) approved
diagnostic test to automate the detection and enumera-
tion of CTCs, for monitoring disease progression and
therapy efficacy in the metastatic prostate, colorectal
and breast cancer [13,14,16,18].
However, in addition to enumeration, molecular char-
acterization of CTCs is very interesting to understand
their biology and discover an association between gene
expression profiles and clinical outcome. Molecular
characterization of CTCs is important not only to con-
firm their malignant origin but also to identify diagnos-
tically and therapeutically relevant targets to help
stratifying cancer patients for individual therapies [30].
Molecular characterization of CTCs can expand our
knowledge of basic molecular pathways of invasion,
migration and immune surveillance and might contri-
bute to the identification of metastatic stem cells with
important implications for the development of improved
therapies in the near future [40]. Assessing the presence
of target antigens on CTCs could be considered as a
real-time biopsy allowing the possibility to evaluate the
change in tumour phenotype during the clinical course
of the disease. A combination of imaging and highly
sensitive multi-parametric molecular methods has been
very recently evaluated for the molecular characteriza-
tion of CTCs [41]. However, the molecular characteriza-
tion of CTCs has been hindered by the very limited
amount of available sample.
By using a combination of multiplex and single RT-
qPCR we quantitatively evaluated the expression profile
of six genes in CTCs isolated from peripheral blood of
early and advanced breast cancer patients: a) CK-19,a n
epithelial biomarker of prognostic significance in early
breast cancer [8-12,28,29], b) HER-2, the therapeutic
target of Trastuzumab (Herceptin) whose expression
status in metastatic sites differs from that of the original
primary tumor in about 5-20% of cases while there is
evidence that nearly one third of patients whose primary
tumors are HER-2/neu negative might have amplified
HER-2/neu on CTCs [19,20], c) MAGE-A3 which was
found to be expressed in 13% of breast cancer patients
and correlated significantly with tumor size and AJCC
stage [42], d) hTERT a+b+, which is critical for the acti-
vation of telomerase [36], e) hMAM (mammaglobin), a
b r e a s tt i s s u es p e c i f i cg e n eo fp r o g n o s t i cv a l u ei nC T C s
[11,37], f) and TWIST-1, an epithelial-mesenchymal
marker which was found to be expressed in 42% in the
CTC (+) group of breast cancer patients by the AdnaT-
est [23].
Our results show that these genes are specifically
e x p r e s s e di nt h eC T Cf r a c t i o na n dn o ti nt h ec o r r e -
sponding isolated fraction from healthy individuals. A
very high percentage of CTC positivity for the expres-
sion of at least one gene was found both in early breast
cancer (72.8%) and metastasis (76.9%). A remarkable
heterogeneity of gene expression was observed for each
individual breast cancer patient, since in a small percen-
tage of patients CTCs were positive for all six genes
tested, while in some patients only one of these genes
was expressed. The clinical significance of these findings
in early breast cancer remains to be elucidated when the
clinical outcome for these patients is known. More than
50% of patients with verified metastasis had ≥ 2 of these
genes expressed. The percentage of CTC positive sam-
ples and the Circulating Tumor Load (expressed as
copies/mL blood) was higher in the group of patients
with verified metastasis, in respect to patients with early
breast cancer. HER-2, mammaglobin and hTERT a+b+
were expressed at very low levels, when compared to
CK-19, TWIST-1 and MAGE A3. According to the very
small number of gene transcripts detected for each gene
target, we can estimate that the number of CTCs/mL of
peripheral blood in early breast cancer is very low. Our
results are in concordance with the AdnaTest [23],
reporting a 42% positivity rate for TWIST1 and a 13%
positivity rate for HER2.
Our preliminary results on the comparison of RT-
qPCR with the CellSearch in the adjuvant setting for a
limited number of patients, have shown a higher positiv-
i t yr a t ei nf a v o ro fR T - q P C R ,d e s p i t et h ef a c tt h a tw e
have used the same amount of peripheral blood and
positive immunomagnetic selection through EpCAM.
This could be possibly explained by the fact that we are
additionally isolating mRNA through oligo-dT beads
and thus we are using the whole isolated mRNA frac-
tion for cDNA synthesis, in combination with the
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Page 9 of 12superior sensitivity of RT-qPCR, as verified at the 10
copies/μL level. To elucidate this, we plan to compare
RT-qPCR and CellSearch in the adjuvant setting for a
large number of patients in the near future. Consistent
with our findings, in a recent study it was reported that
there was no association in the detection rates of CTCs
from patients with breast cancer when the same samples
were analyzed by both the CellSearch and the AdnaTest:
18.4% of patients with primary breast cancer were posi-
tive by CellSearch and 35.7% by the AdnaTest [43].
The main limitation of the molecular methods in
comparison to the imaging approaches (CellSearch), is
the fact that they cannot provide information at the sin-
gle cell level, eg whether the same CTC is expressing all
target genes studied or whether more than one CTC is
present, each expressing a different target gene. How-
ever, molecular methods such as RT-qPCR in compari-
son to the imaging approaches, have the potential of
giving information for the presence of multiple targets
in CTCs, are characterized by high sensitivity and speci-
ficity, even at the single cell level, while at the same
time the expression of gene targets at the mRNA level
can only be achieved through the isolation of viable and
not apoptotic CTCs [23,28-30]. Moreover RT-qPCR, is
performed in a closed tube and high throughput auto-
mated format, can be easily intergraded in external qual-
ity control programs, is cheaper and very practical for
clinical labs that analyze a large number of patient’s
samples. Further improvements on CTC isolation tech-
nologies are needed, while a combination of imaging
and highly sensitive multi-parametric molecular meth-
ods in large scale predictive biomarker studies will
enable the establishment of CTCs in the clinical setting.
Conclusions
By using a combination of multiplex and single RT-
qPCR we quantitatively evaluated the expression profile
of CK-19, MAGE-A3, HER-2, TWIST1, hTERT a+b+,
and mammaglobin in CTCs isolated from peripheral
blood of early and advanced breast cancer patients. Our
study has revealed a remarkable heterogeneity of gene
expression between breast cancer patients and shows
that these genes are specifically expressed in the CTC
fraction and not in the corresponding isolated fraction
from healthy individuals. A very high percentage of
CTC positivity for the expression of at least one gene
was found both in early breast cancer and metastasis. A
remarkable heterogeneityo fg e n ee x p r e s s i o nw a s
observed for each individual breast cancer patient. In a
small percentage of patients, CTCs were positive for all
six genes tested, while in some patients only one of
these genes was expressed. More than 50% of patients
with verified metastasis had ≥ 2o ft h e s eg e n e s
expressed. Our preliminary results on the comparison of
RT-qPCR with the CellSearch in the adjuvant setting for
a limited number of patients, have shown a higher posi-
tivity rate in favor of RT-qPCR, despite the fact that we
have used the same amount of peripheral blood and
positive immunomagnetic selection through EpCAM.
The clinical significance of these findings in early breast
cancer remains to be elucidated when the clinical out-
come for these patients is known.
Additional material
Additional file 1: Figure S1. Specificity of multiplex RT-qPCR for CK-
19, MAGE A3, HER-2 and PBGD. Specificity of primers and dual
hybridization probes both in the presence and absence of each gene
target.
Additional file 2: Figure S2. Quantification of CK-19, MAGE A3, HER-
2, PBGD mRNA-positive cells by multiplex RT-qPCR (copies/μL,
measured in triplicate). Evaluation of the limit of detection of the
developed CTC gene expression RT-qPCR assay by using quantification
calibrators containing a known number of copies/μL.
List of abbreviations
BM: bone marrow; CK-19: cytokeratin 19; CTCs: circulating tumor cells; DTCs:
disseminated tumor cells; EMT: epithelial mesenchymal transition; ER:
estrogen receptor; HER-2: human epidermal growth factor receptor 2; h-TERT:
human telomerase reverse transcriptase; LOD: limit of detection; LOQ: limit
of quantification; PBGD: porphobilinogen deaminase; PR: progesterone
receptor; RT-qPCR: Reverse Transcription quantitative Polymerase Chain
Reaction; MAGE-A3: Melanoma-associated antigen 3
Acknowledgements and Funding
We would like to thank especially Dr. D. Christou and Dr. N. Mavroidis for
their support through-out this study. This work was supported by a PENED
grant of the Greek General Secretariat of Research and Technology and
Bioanalytica SA.
Author details
1Department of Chemistry, University of Athens, University Campus, 15771,
Athens, Greece.
2Department of Medical Oncology, University of Crete,
71110, Crete, Greece.
Authors’ contributions
EL designed, and supervised the project; AS, AM and EL developed the
assay; AS and AM performed most of the experiments; CP performed h-TERT
expression study in CTCs; EP performed the Cell Search measurements in
CTCs; VG and DM provided the clinical samples; AS and EL wrote the
manuscript; All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 16 December 2010 Accepted: 4 October 2011
Published: 4 October 2011
References
1. Nguyen DX, Bos PD, Massagué J: Metastasis: from dissemination to organ-
specific colonization. Nat Rev Cancer 2009, 9:274-84.
2. Pantel K, Brakenhoff RH: Dissecting the metastatic cascade. Nat Rev Cancer
2004, 4:448-56.
3. Klein CA: Parallel progression of primary tumours and metastases. Nat
Rev Cancer 2009, 9:302-12.
4. Aguirre-Ghiso AJulio: Models, mechanisms and clinical evidence for
cancer dormancy. Nat Rev Cancer 2007, 7:834-46.
Strati et al. BMC Cancer 2011, 11:422
http://www.biomedcentral.com/1471-2407/11/422
Page 10 of 125. Pantel K, Alix-Panabières C, Riethdorf S: Cancer micrometastases. Nat Rev
Clin Oncol 2009, 6:339-51.
6. Ashworth TR: A case of cancer in which cells similar to those in the
tumours were seen in the blood after death. Aust Med J 1869, 14:146-149.
7. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC,
Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D,
Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J,
Vincent-Salomon A, Pantel K: A pooled analysis of bone marrow
micrometastasis in breast cancer. N Engl J Med 2005, 353:793-802.
8. Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis Ch,
Apostolaki S, Malamos N, Kakolyris S, Kotsakis A, Xenidis N, Reppa D,
Georgoulias V: Molecular detection of cytokeratin-19-positive cells in the
peripheral blood of patients with operable breast cancer: evaluation of
their prognostic significance. J Clin Oncol 2002, 20:3404-12.
9. Xenidis N, Vlachonikolis I, Mavroudis D, Perraki M, Stathopoulou A,
Malamos N, Kouroussis C, Kakolyris S, Apostolaki S, Vardakis N, Lianidou E,
Georgoulias V: Peripheral blood circulating cytokeratin-19 mRNA-positive
cells after the completion of adjuvant chemotherapy in patients with
operable breast cancer. Ann Oncol 2003, 14:849-55.
10. Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A,
Kalbakis K, Androulakis N, Kouroussis C, Pallis T, Christophylakis C, Argyraki K,
Lianidou ES, Stathopoulos S, Georgoulias V, Mavroudis D: Predictive and
prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells
detected by real-time polymerase chain reaction in node-negative
breast cancer patients. J Clin Oncol 2006, 24:3756-62.
11. Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M,
Chlouverakis G, Stathopoulos E, Lianidou E, Georgoulias V, Mavroudis D:
Prognostic value of the molecular detection of circulating tumor cells
using a multimarker reverse transcription-PCR assay for cytokeratin 19,
mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res 2008,
14:2593-600.
12. Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M,
Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C,
Georgoulias V, Mavroudis D: Different prognostic value of cytokeratin-19
mRNA positive circulating tumor cells according to estrogen receptor
and HER2 status in early-stage breast cancer. J Clin Oncol 2007,
25:5194-202.
13. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM,
Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN,
Terstappen LW: Circulating tumor cells: a novel prognostic factor for
newly diagnosed metastatic breast cancer. J Clin Oncol 2005, 23:1420-30.
14. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM,
Doyle GV, Allard WJ, Terstappen LW, Hayes DF: Circulating tumor cells,
disease progression, and survival in metastatic breast cancer. N Engl J
Med 2004, 351:781-91.
15. Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S,
Stathopoulos EN, Chlouverakis G, Lianidou E, Kakolyris S, Georgoulias V,
Mavroudis D: Cytokeratin-19 mRNA-positive circulating tumor cells after
adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol
2009, 27:2177-84.
16. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H,
Doyle GV, Terstappen LW, Pienta KJ, Raghavan D: Circulating tumor cells
predict survival benefit from treatment in metastatic castration-resistant
prostate cancer. Clin Cancer Res 2008, 14:6302-9.
17. Ignatiadis M, Georgoulias V, Mavroudis D: Circulating tumor cells in breast
cancer. Curr Opin Obstet Gynecol 2008, 20:55-60.
18. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G:
Circulating tumour cells as prognostic markers in progressive, castration-
resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol
2009, 10:233-9.
19. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A,
Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E,
Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N,
Wang J, Uhr J: HER-2 gene amplification can be acquired as breast
cancer progresses. Proc Natl Acad Sci USA 2004, 101:9393-8.
20. Bozionellou V, Mavroudis D, Perraki M, Papadopoulos S, Apostolaki S,
Stathopoulos E, Stathopoulou A, Lianidou E, Georgoulias V: Trastuzumab
administration can effectively target chemotherapy-resistant cytokeratin-
19 messenger RNA-positive tumor cells in the peripheral blood and
bone marrow of patients with breast cancer. Clin Cancer Res 2004,
10:8185-94.
21. Müller V, Pantel K: HER2 as marker for the detection of circulating tumor
cells. Breast Cancer Res Treat 2009, 117:535-7.
22. Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, Datar RH,
Cote RJ: Most early disseminated cancer cells detected in bone marrow
of breast cancer patients have a putative breast cancer stem cell
phenotype. Clin Cancer Res 2006, 12:5615-21.
23. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S: Stem cell
and epithelial-mesenchymal transition markers are frequently
overexpressed in circulating tumor cells of metastatic breast cancer
patients. Breast Cancer Res 2009, 11:R46.
24. Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, Schindlbeck C,
Wallwiener D, Borgen E, Naume B, Pantel K, Solomayer E: A concept for
the standardized detection of disseminated tumor cells in bone marrow
from patients with primary breast cancer and its clinical
implementation. Cancer 2006, 107:885-92.
25. Ring AE, Zabaglo L, Ormerod MG, Smith IE, Dowsett M: Detection of
circulating epithelial cells in the blood of patients with breast cancer:
comparison of three techniques. Br J Cancer 2005, 92:906-12.
26. Reinholz MM, Nibbe A, Jonart LM, Kitzmann K, Suman VJ, Ingle JN,
Houghton R, Zehentner B, Roche PC, Lingle WL: Evaluation of a panel of
tumor markers for molecular detection of circulating cancer cells in
women with suspected breast cancer. Clin Cancer Res 2005, 11:3722-32.
27. Hartmann CH, Klein CA: Gene expression profiling of single cells on
large-scale oligonucleotide arrays. Nucleic Acids Res 2006, 34:e143.
28. Stathopoulou A, Gizi A, Perraki M, Apostolaki S, Malamos N, Mavroudis D,
Georgoulias V, Lianidou ES: Real-time quantification of CK-19 mRNA-
positive cells in peripheral blood of breast cancer patients using the
lightcycler system. Clin Cancer Res 2003, 9:5145-51.
29. Stathopoulou A, Ntoulia M, Perraki M, Apostolaki S, Mavroudis D,
Malamos N, Georgoulias V, Lianidou ES: A highly specific real-time RT-PCR
method for the quantitative determination of CK-19 mRNA positive cells
in peripheral blood of patients with operable breast cancer. Int J Cancer
2006, 119:1654-9.
30. Sieuwerts AM, Kraan CJ, Bolt-de Vries J, van der Spoel P, Mostert B,
Martens JW, Gratama J, Sleijfer S, Foekens JA: Molecular characterization of
circulating tumor cells in large quantities of contaminating leukocytes
by a multiplex real-time PCR. Breast Cancer Res Treat 2009, 118:455-468.
31. Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, Janni W,
Coith C, Beck K, Jänicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K:
Detection of circulating tumor cells in peripheral blood of patients with
metastatic breast cancer: a validation study of the CellSearch system.
Clin Cancer Res 2007, 13:920-8.
32. Kallergi G, Markomanolaki H, Giannoukaraki V, Papadaki MA, Strati A,
Lianidou ES, Georgoulias V, Mavroudis D, Agelaki S: Hypoxia-inducible
factor-1alpha and vascular endothelial growth factor expression in
circulating tumor cells of breast cancer patients. Breast Cancer Res 2009,
11:R84.
33. Zheng S, Lin H, Liu JQ, Balic M, Datar R, Cote RJ, Tai YC: Membrane
microfilter device for selective capture, electrolysis and genomic analysis
of human circulating tumor cells. J Chromatogr A 2007, 1162:154-61.
34. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR,
Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG,
Haber DA, Toner M: Isolation of rare circulating tumour cells in cancer
patients by microchip technology. Nature 2007, 450:1235-9.
35. Wittwer CT, Herrmann MG, Gundry CN, Elenitoba-Johnson KS: Real-time
multiplex PCR assays. Methods 2001, 25:430-42.
36. Mavrogiannou E, Strati A, Stathopoulou A, Tsaroucha EG, Kaklamanis L,
Lianidou ES: Real-time RT-PCR quantification of human telomerase
reverse transcriptase splice variants in tumor cell lines and non-small
cell lung cancer. Clin Chem 2007, 53:53-61.
37. Ntoulia M, Stathopoulou A, Ignatiadis M, Malamos N, Mavroudis D,
Georgoulias V, Lianidou ES: Detection of Mammaglobin A-mRNA-positive
circulating tumor cells in peripheral blood of patients with operable
breast cancer with nested RT-PCR. Clin Biochem 2006, 39:879-87.
38. Sambrook J, Fritsch EF, Maniatis T: Molecular cloning: a laboratory manual.
Cold Spring Harbor Laboratory Press Cold Spring Harbor, NY;, 2 1989.
39. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R,
Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer : The MIQE
Guidelines Minimum Information for Publication of Quantitative Real-
Time PCR Experiments. Clin Chem 2009, 55:611-622.
Strati et al. BMC Cancer 2011, 11:422
http://www.biomedcentral.com/1471-2407/11/422
Page 11 of 1240. Korkaya H, Wicha MS: HER-2, notch, and breast cancer stem cells:
targeting an axis of evil. Clin Cancer Res 2009, 15:1845-7.
41. Punnoose EA, Atwal SK, Spoerke JM, Savage H, Pandita A, Yeh RF, Pirzkall A,
Fine BM, Lukas C, Amler LC, Chen DS, Lackner MR: Molecular Biomarker
Analyses Using Circulating Tumor Cells. PLoS ONE 2010, 5:e12517.
42. Taback B, Chan AD, Kuo CT, Bostick PJ, Wang HJ, Giuliano AE, Hoon DS:
Detection of occult metastatic breast cancer cells in blood by a
multimolecular marker assay: correlation with clinical stage of disease.
Cancer Res 2001, 61:8845-50.
43. Mego M, Mani SA, Lee BN, Li C, Evans KW, Cohen EN, Gao H, Jackson SA,
Giordano A, Hortobagyi GN, Cristofanilli M, Lucci A, Reuben JM: Expression
of epithelial-mesenchymal transition-inducing transcription factors in
primary breast cancer: The effect of neoadjuvant therapy. Int J Cancer
2011.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/11/422/prepub
doi:10.1186/1471-2407-11-422
Cite this article as: Strati et al.: Gene expression profile of circulating
tumor cells in breast cancer by RT-qPCR. BMC Cancer 2011 11:422.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Strati et al. BMC Cancer 2011, 11:422
http://www.biomedcentral.com/1471-2407/11/422
Page 12 of 12